Evidence map›Paper›PMID 24005245›Full record

ArticleLeukemia2014

Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT.

A Ruggeri, G Sanz, H Bittencourt, J Sanz, A Rambaldi, F Volt, I Yakoub-Agha, J M Ribera, L Mannone, J Sierra and 8 more

Registry-linked trialOpen access · greenAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02385955 (Prospective Multicenter Phase II Study of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adult Patients With Hematologic Malignancies), which is not on this map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02385955 phase2unknown statusnot on this mapstarted 2015, after this paper: background citation

Prospective Multicenter Phase II Study of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adult Patients With Hematologic Malignancies

TypeinterventionalSponsorSeoul National University HospitalRan2015 to 2019Enrolled39ConditionsHematologic MalignancyArmsMyeloablative double unit cord blood transplantation
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 98 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Article
  15. Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Article
  16. Article
  17. Article
  18. Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 5 countries.

A Ruggeri1] Eurocord, Hôpital Saint Louis, AP-HP, and IUH University Paris VII, Paris, France [2] Rome Transplant Network, University Tor Vergata, Rome, Italy.
G SanzHospital Universitario La Fe, Valencia, Spain.
H BittencourtCHU Sainte-Justine, Montreal, QC, Canada.
J SanzHospital Universitario La Fe, Valencia, Spain.
A RambaldiOspedali Riuniti di Bergamo, Bergamo, Italy.
F VoltEurocord, Hôpital Saint Louis, AP-HP, and IUH University Paris VII, Paris, France.
I Yakoub-AghaHôpital Claude Huriez, Lille, France.
J M RiberaICO-Hospital Universitari Germans Trias i Pujol, Jose Carreras Research Institute, Badalona, Spain.
L MannoneHôpital l'Archet, Nice, France.
J SierraHospital Santa Creu i Sant Pau, Barcelona, Spain.
M MohtyHospital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, AP-HP, UPMC Univ Paris 06, UMR-S 938, CEREST-TC EBMT, Paris, France.
C SolanoHospital Clínico Universitario, Valencia, Spain.
S NabhanEurocord, Hôpital Saint Louis, AP-HP, and IUH University Paris VII, Paris, France.
W ArceseRome Transplant Network, University Tor Vergata, Rome, Italy.
E GluckmanEurocord, Hôpital Saint Louis, AP-HP, and IUH University Paris VII, Paris, France.
M LabopinHospital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, AP-HP, UPMC Univ Paris 06, UMR-S 938, CEREST-TC EBMT, Paris, France.
V Rocha1] Eurocord, Hôpital Saint Louis, AP-HP, and IUH University Paris VII, Paris, France [2] Churchill Hospital, Oxford University Hospitals, Oxford, UK.
Eurocord and Acute Leukemia Working Party of European Blood and Marrow Transplant Group
Hôpital Saint-Louis · FRHospital Universitari i Politècnic La Fe · ESSorbonne Université · FRUniversité Paris Cité · FRCentre Hospitalier Universitaire Sainte-Justine · CAHôpital Claude Huriez · FRHôpital l'Archet · FRHospital Clínico Universitario de Valencia · ESHospital de Sant Pau · ESHospital Universitari Germans Trias i Pujol · ESUniversity of Bergamo · ITUniversity of Oxford · GBUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report outcomes after single (s) and double (d) umbilical cord blood transplantation (UCBT) after myeloablative conditioning (MAC) regimen for 239 patients transplanted for acute leukemia in first complete remission (CR1). All sUCBT patients received a total nucleated cell dose >2.5 × 10(7)/kg. Conditioning regimen for sUCBT was total body irradiation (TBI)12 Gy- or busulfan (BU)-based ± fludarabine (Flu) (n=68, group 1), thiotepa+BU+Flu (TBF) (n=88, group 2), and for dUCBT it was TBI12 Gy+cyclophosphamide ± Flu (n=83, group 3). dUCBT recipients were younger, received higher cell dose and less frequently antithymocyte globulin. In multivariate analysis, we found similar neutrophil recovery among the three groups; however, acute graft-versus-host disease II-IV was higher in dUCBT compared with others. Non-relapse mortality and relapse incidence were not statistically different among the three groups. Leukemia-free survival was 30% for sUCBT using TBI- or BU-based MAC compared with 48% for sUCBT TBF and 48% for dUCBT (P=0.02 and P=0.03, respectively), and it was not statistically different between sUCBT with TBF and dUCBT. In conclusion, use of sUCBT with adequate cell dose (>2.5 × 10(7)/kg) and a specific conditioning regimen in the MAC setting results in similar outcomes as dUCBT. The choice of TBF conditioning regimen for sUCBT may improve results, and whether this regimen may be effective in dUCBT should be further analyzed.

Indexed as

Cord Blood Stem Cell TransplantationTransplantation ConditioningAdolescentAdultAntigens, CD34FemaleGraft vs Host DiseaseHumansLeukemia, Myeloid, AcuteMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesTreatment OutcomeAntigens, CD34

Identifiers

PMID24005245
OpenAlexW1969322812

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.